Form 4: Gilead CFO Sells Shares Under Pre-Arranged 10b5-1 Plan

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of common stock for $122 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc. (GILD), disposed of 3,000 shares of the company's common stock.
• The transaction occurred on December 15, 2025, at a price of $122 per share.
• This sale was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted on August 29, 2024.
• Following this transaction, Dickinson beneficially owns 153,503 shares of Gilead Sciences common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive due to the transparency provided by the Rule 10b5-1 plan, which indicates a pre-scheduled transaction rather than a reactive one, mitigating potential negative interpretations of insider selling.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled and transparent sale, which helps mitigate concerns about opportunistic insider trading.

Negatives

• The sale of shares by a key executive, even if pre-planned, can sometimes be interpreted by the market as a slight reduction in insider confidence or a move to diversify personal holdings.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider transaction for Gilead Sciences and does not provide information relevant to broader industry trends or competitor analysis.

Corporate Governance

Stakeholder Impact

• Shareholders may view the sale of shares by a key executive with slight caution, though the pre-planned nature under a 10b5-1 plan generally reduces concerns about a lack of confidence in the company's future.

Key Dates

Recommendation

The filing reports a pre-scheduled sale of shares by the CFO under a Rule 10b5-1 plan. While insider selling can sometimes be a negative signal, the pre-planned nature suggests it's for personal financial management rather than a reaction to new, undisclosed negative information. The transaction itself does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Gilead Sciences, GILD, Form 4, Insider Trading, Stock Sale, CFO, Andrew D. Dickinson, 10b5-1 Plan